Gapping up
In reaction to earnings/guidance:
- SLQT +14.9%, BECN +6.5%, IIVI +5.4%, GT +5.3%, VRNS +5.1% (also announces 3-for-1 stock split), CHGG +4.1%, OMF +3.5%, CAMT +3.1%, IT +2.7%, BBDC +2.4%, HAIN +2.4%, SEE +2.2%, SPG +2.1%, HBI +2%, EPC +1.8%, ARMK +1.8%, MBUU +1.7%, SPGI +1.7%, INCY +1.5%, HMC +1.2%, CGC +1.1%, AVYA +1.1%, BLKB +0.9%, J +0.8%, DD +0.7%, MLM +0.7%
Other news:
- KALV +178.9% (announces "positive" topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks)
- HTBX +62.7% (reports positive interim data of the co's fully-enrolled Phase 2 trial of HS-110)
- GLUU +33.3% (EA to acquire GLUU for $12.50/sh in cash; also reported earnings)
- TLRY +19.3% (established an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom)
- IRWD +12.8% (CEO departs),
- COLL +11.9% (to be added to the S&P SmallCap 600)
- GRNV +11.5% (to combine with Helbiz; deal includes $30 mln PIPE investment)
- NCTY +9.4% (enters into a $100 mln SEDA to fund business growth)
- FRLN +8.3% (presents data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies)
- ORTX +7.3% (announces new data from several of its hematopoietic stem cell gene therapies in development for neurodegenerative disorders, including interim data on multiple clinical outcomes for OTL-203 in MPS-I, encouraging preliminary biomarker data for OTL-201 in MPS-IIIA and natural history data in MLD)
- IPHA +6.3% (announced new clinical developments for its first-in-class, proprietary investigational asset, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas)
- SAIC +6.3% (awarded $830 mln Army contract for Aviation Systems Engineering Services)
- AVIR +5.8% (announces publication of preclinical data for AT-5270)
- TIGR +5.6% (announces $65 mln private placement of convertible notes)
- IPI +4.3% (announces $50 increase to potash price)
- AFMD +4.2% (Point72 Asset Mgmt discloses 4.8% stake (prior 1.72%))
- VERI +2% (continues international expansion through agreement with Lima, Peru-based commercial radio group, CRP Radios)
- MPWR +1.7% (to be added to the S&P 500)
- TEN +1.3% (Carl Icahn lowers active stake following the recent sale)
- BIDU +1.3% (develops first multi-modal autonomous driving MaaS platform in Guangzhou)
- TGTX +1.3% (license partner Rhizen Pharmaceuticals AG receives FDA accelerated approval for Umbralisib for adult patients with relapsed or refractory MZL & FL)
- AMRN +1.1% (provides update on regulatory review processes for Vascepa in Mainland China and Hong Kong)
Analyst comments:
- TWLO +2.6% (upgraded to Overweight from Neutral at JP Morgan)
- KREF +2.3% (upgraded to Overweight from Neutral at JP Morgan)
- EQR +1.4% (upgraded to Buy from Neutral at BofA Securities)
- HSBC +1% (upgraded to Neutral from Underperform at BofA Securities; upgraded to Sector Perform from Underperform at RBC Capital Mkts)